A new drug cleared 91% of brain amyloid plaques in 7 months, showing faster results than current Alzheimer's treatments and advancing to Phase III trials in 2025.

This graphene foam biosensor offers high sensitivity for tau protein detection, enabling early Alzheimer's diagnosis and ...